Lu LG, Zeng MD, Mao YM, Li JQ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol 2003; 9(12): 2796-2800 [PMID: 14669336 DOI: 10.3748/wjg.v9.i12.2796]
Corresponding Author of This Article
Dr. Lun-Gen Lu, MD, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China. lulungen@online.sh.cn
Article-Type of This Article
Clinical Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 15, 2003; 9(12): 2796-2800 Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2796
Table 1 Relationship between clinical manifestations and pathological grading and staging of liver tissues
Groups
Symptom score + physical signs
n
Inflammatory grading ( G ) (%)
Fibrosis staging (s) (%)
1
2
3
4
0
1
2
3
4
1
0~1+ no hepatomegaly and splenomegaly
15
46.7
40
13.3
0
33.3
26.7
40
0
0
2
0~1+ hepatomegaly and splenomegaly
14
28.6
28.6
28.6
14.3
7.1
35.7
28.6
14.3
14.3
3
~3+no hepatomegaly and splenomegaly
28
42.9
53.6
3.5
0
14.3
50
35.7
0
0
4
2~3 +hepatomegaly and splenomegaly
42
30.9
26.2
28.5
16.7
9.5
23.8
40.5
16.7
9.5
5
4+ no hepatomegaly and splenomegaly
32
43.7
25
15.6
15.6
12.5
34.3
25
15.6
12.5
6
4+ hepatomegaly and splenomegaly
69
23.3
21.7
34.8
15.9
2.9
29
29
15.9
23.2
P < 0.01
P < 0.01
Table 2 Relationship between biochemical parameters and inflammatory grading and fibrosis staging
Parameters
Inflammatory (G) (%)
Fibrosis staging (s) (%)
1~2
1~3
1~4
2~3
2~4
3~4
0~1
0~2
0~3
0~4
1~2
1~3
1~4
2~3
2~4
3~4
RBC
b
b
b
a
a
a
a
PLT
b
b
b
AST
b
b
a
b
ALT
AST/ALT
GGTa
a
b
b
b
b
b
b
b
b
b
A
b
b
b
b
b
b
A/G
b
b
b
b
b
b
HA
b
b
b
b
b
b
b
b
b
b
b
b
b
LN
7S-IV
a
b
a
b
a
a
a
PIIINP
b
b
AFP
b
b
b
b
b
b
b
b
b
b
b
PT
Table 3 Serologic parameters for diagnosing liver fibrosis and cirrhosis
Parameters
Fibrosis (S0/S1~4)
Cirrhosis (S1~3/S4)
Specificity (%)
Sensitivity (%)
Accuracy (%)
Specificity (%)
Sensitivity (%)
Accuracy (%)
HA
94.44
38.26
43.50
90.0
60.0
85.71
PIIINP
16.67
77.71
72.0
78.0
24.0
70.28
LN
55.26
50.29
50.10
54.0
52.0
53.71
7S-IV
50.22
24.67
51.0
93.29
24.0
89.08
Table 4 Serologic parameters for diagnosing liver fibrosis and cirrhosis
Parameters
Fibrosis (S0/S1~4)
Cirrhosis (S1~3/S4)
Specificity (%)
Sensitivity (%)
Accuracy (%)
Specificity (%)
Sensitivity (%)
Accuracy (%)
HA+7S-IV
88.89
37.93
42.50
89.93
60.0
85.63
HA+PIIINP
88.89
42.86
47.10
90.0
60.0
85.71
HA+7S-IV+
88.89
47.13
51.04
89.93
64.0
86.21
PIIINP+LN
HA+TIMP
92.86
38.28
43.67
90.27
60.0
86.72
PGA+HA
60.0
60.44
60.40
89.41
66.67
87.91
PGAA+HA
70.0
62.64
63.67
89.41
66.67
87.91
PGA+7S-IV
61.12
50.22
50.31
90.59
33.33
86.80
PGAA+7S-IV
60.0
48.22
50.67
92.94
33.33
89.0
Citation: Lu LG, Zeng MD, Mao YM, Li JQ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol 2003; 9(12): 2796-2800